Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MGTXNASDAQ:MNMDNASDAQ:TNXPNASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMGTXMeiraGTx$5.47+1.1%$6.44$3.85▼$8.75$432.54M1.3343,154 shs672,229 shsMNMDMind Medicine (MindMed)$6.46-2.0%$6.12$4.70▼$10.44$486.88M2.521.39 million shs1.20 million shsTNXPTonix Pharmaceuticals$18.93-1.1%$17.77$6.76▼$672.00$121.78M1.63797,495 shs431,506 shsURGNUroGen Pharma$10.67+5.4%$10.62$8.94▼$20.70$491.73M0.66540,455 shs603,180 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMGTXMeiraGTx-7.84%-23.70%-5.91%-22.16%+0.56%MNMDMind Medicine (MindMed)+4.12%+2.90%+21.09%-26.70%-31.15%TNXPTonix Pharmaceuticals+0.93%+5.80%+7.05%+69.53%-96.93%URGNUroGen Pharma+4.47%-13.03%+1.64%-7.55%-24.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMGTXMeiraGTx4.4353 of 5 stars3.52.00.04.81.82.51.9MNMDMind Medicine (MindMed)2.4913 of 5 stars3.63.00.00.02.90.80.6TNXPTonix Pharmaceuticals2.4297 of 5 stars3.52.00.00.02.01.71.3URGNUroGen Pharma4.4589 of 5 stars4.52.00.04.53.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMGTXMeiraGTx 3.00Buy$24.50347.90% UpsideMNMDMind Medicine (MindMed) 3.23Buy$25.11288.72% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.002,991.15% UpsideURGNUroGen Pharma 3.00Buy$32.86208.08% UpsideCurrent Analyst Ratings BreakdownLatest TNXP, MNMD, MGTX, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/29/2025URGNUroGen PharmaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/28/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.004/28/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.004/17/2025URGNUroGen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$22.00 ➝ $16.004/16/2025URGNUroGen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$23.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/17/2025MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$11.00 ➝ $13.003/11/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $55.003/10/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/7/2025MNMDMind Medicine (MindMed)Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$27.00 ➝ $16.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMGTXMeiraGTx$33.28M13.14N/AN/A$2.17 per share2.52MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ATNXPTonix Pharmaceuticals$10.09M12.06N/AN/A$5,751.80 per share0.00URGNUroGen Pharma$90.40M5.44N/AN/A($2.78) per share-3.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMGTXMeiraGTx-$84.03M-$2.13N/A14.390.37-633.05%-146.38%-53.05%5/8/2025 (Estimated)MNMDMind Medicine (MindMed)-$95.73M-$2.08N/AN/AN/AN/A-47.56%-35.55%5/8/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%5/12/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.23N/AN/AN/A-129.11%N/A-47.94%5/12/2025 (Estimated)Latest TNXP, MNMD, MGTX, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23N/AN/AN/A$2.55 millionN/A5/12/2025Q1 2025URGNUroGen Pharma-$0.83N/AN/AN/A$22.71 millionN/A5/8/2025Q1 2025MGTXMeiraGTx-$0.38N/AN/AN/A$4.44 millionN/A5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 million3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 million3/10/2025Q4 2024URGNUroGen Pharma-$0.69-$0.80-$0.11-$0.80$25.25 million$24.57 million3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMGTXMeiraGTxN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMGTXMeiraGTx0.862.342.34MNMDMind Medicine (MindMed)0.099.009.00TNXPTonix Pharmaceuticals0.073.332.81URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMGTXMeiraGTx67.48%MNMDMind Medicine (MindMed)27.91%TNXPTonix Pharmaceuticals82.26%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipMGTXMeiraGTx8.40%MNMDMind Medicine (MindMed)2.26%TNXPTonix Pharmaceuticals0.03%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMGTXMeiraGTx30079.95 million71.59 millionOptionableMNMDMind Medicine (MindMed)4075.37 million71.68 millionOptionableTNXPTonix Pharmaceuticals506.44 million1.87 millionNot OptionableURGNUroGen Pharma20046.11 million22.26 millionOptionableTNXP, MNMD, MGTX, and URGN HeadlinesRecent News About These CompaniesUroGen's bladder cancer treatment to be reviewed by FDA advisory committeeMay 7 at 11:54 AM | msn.comUroGen Pharma (URGN) Expected to Announce Earnings on MondayMay 7 at 8:28 AM | marketbeat.comCantor Fitzgerald L. P. Takes $3.79 Million Position in UroGen Pharma Ltd. (NASDAQ:URGN)May 7 at 6:53 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Shares Bought by Price T Rowe Associates Inc. MDMay 7 at 4:08 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by JPMorgan Chase & Co.May 6 at 3:05 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of "Buy" from BrokeragesMay 6 at 2:21 AM | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from BrokeragesMay 5 at 2:25 AM | americanbankingnews.comAcorn Capital Advisors LLC Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)May 4, 2025 | marketbeat.comHC Wainwright Comments on UroGen Pharma Q1 EarningsMay 2, 2025 | marketbeat.comHC Wainwright Predicts UroGen Pharma Q1 EarningsMay 2, 2025 | americanbankingnews.comUroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 1, 2025 | businesswire.comGuggenheim Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)May 1, 2025 | marketbeat.comMarshall Wace LLP Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)May 1, 2025 | marketbeat.comUroGen Pharma's (URGN) Buy Rating Reaffirmed at GuggenheimMay 1, 2025 | americanbankingnews.comUroGen Pharma (NASDAQ:URGN) Trading Up 10.8% - Here's What HappenedApril 30, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Earns Buy Rating from HC WainwrightApril 30, 2025 | marketbeat.comNantahala Capital Management LLC Takes Position in UroGen Pharma Ltd. (NASDAQ:URGN)April 30, 2025 | marketbeat.comJump Financial LLC Lowers Position in UroGen Pharma Ltd. (NASDAQ:URGN)April 30, 2025 | marketbeat.comRenaissance Technologies LLC Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN)April 30, 2025 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Earns "Buy" Rating from HC WainwrightApril 30, 2025 | americanbankingnews.comUrogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?April 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP, MNMD, MGTX, and URGN Company DescriptionsMeiraGTx NASDAQ:MGTX$5.47 +0.06 (+1.11%) Closing price 04:00 PM EasternExtended Trading$5.47 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Mind Medicine (MindMed) NASDAQ:MNMD$6.46 -0.13 (-1.97%) Closing price 04:00 PM EasternExtended Trading$6.46 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Tonix Pharmaceuticals NASDAQ:TNXP$18.92 -0.22 (-1.12%) Closing price 03:59 PM EasternExtended Trading$18.96 +0.04 (+0.21%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.UroGen Pharma NASDAQ:URGN$10.66 +0.55 (+5.39%) Closing price 03:59 PM EasternExtended Trading$10.32 -0.35 (-3.28%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
